Global Alpha Capital Management Ltd. Has $46.59 Million Position in ANI Pharmaceuticals, Inc. $ANIP

Global Alpha Capital Management Ltd. reduced its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 6.4% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 590,135 shares of the specialty pharmaceutical company’s stock after selling 40,455 shares during the period. ANI Pharmaceuticals comprises 2.8% of Global Alpha Capital Management Ltd.’s portfolio, making the stock its 9th biggest position. Global Alpha Capital Management Ltd.’s holdings in ANI Pharmaceuticals were worth $46,585,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Advisors Asset Management Inc. bought a new stake in ANI Pharmaceuticals during the 1st quarter valued at $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in ANI Pharmaceuticals by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company’s stock valued at $736,000 after purchasing an additional 470 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in ANI Pharmaceuticals by 0.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company’s stock valued at $3,235,000 after purchasing an additional 423 shares in the last quarter. Jane Street Group LLC bought a new stake in ANI Pharmaceuticals during the 1st quarter valued at $2,706,000. Finally, Norges Bank bought a new stake in ANI Pharmaceuticals during the 2nd quarter valued at $625,000. 76.05% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

ANIP has been the subject of a number of research analyst reports. Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Wall Street Zen upgraded ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a report on Monday, June 1st. Five research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $107.33.

ANI Pharmaceuticals Trading Up 2.4%

Shares of NASDAQ:ANIP opened at $81.11 on Friday. ANI Pharmaceuticals, Inc. has a 12-month low of $59.89 and a 12-month high of $99.50. The business’s fifty day simple moving average is $79.06 and its 200-day simple moving average is $79.39. The company has a market capitalization of $1.85 billion, a PE ratio of 20.53 and a beta of 0.44. The company has a current ratio of 3.12, a quick ratio of 2.52 and a debt-to-equity ratio of 1.06.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.77. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The firm had revenue of $237.46 million for the quarter, compared to the consensus estimate of $207.63 million. During the same period in the previous year, the business earned $1.70 EPS. The firm’s revenue for the quarter was up 20.5% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities research analysts predict that ANI Pharmaceuticals, Inc. will post 8.07 earnings per share for the current fiscal year.

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, VP Meredith Cook sold 500 shares of the business’s stock in a transaction dated Wednesday, May 13th. The stock was sold at an average price of $78.16, for a total transaction of $39,080.00. Following the sale, the vice president owned 78,390 shares in the company, valued at approximately $6,126,962.40. The trade was a 0.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Thomas Andrew Rowland sold 459 shares of the business’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $79.21, for a total value of $36,357.39. Following the sale, the senior vice president owned 38,271 shares in the company, valued at approximately $3,031,445.91. The trade was a 1.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 81,638 shares of company stock worth $6,348,562. 8.10% of the stock is owned by corporate insiders.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.